1
|
Yang R, Han S, Clayton J, Haghighatian M, Tsai C, Yao Y, Li P, Shen J, Zhou Q. A Proof-of-Concept Inhibitor of Endothelial Lipase Suppresses Triple-Negative Breast Cancer Cells by Hijacking the Mitochondrial Function. Cancers (Basel) 2022; 14:3763. [PMID: 35954428 PMCID: PMC9367514 DOI: 10.3390/cancers14153763] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 07/24/2022] [Accepted: 07/30/2022] [Indexed: 02/01/2023] Open
Abstract
Simple Summary Endothelial lipase (EL/LIPG) is a key regulator of tumor cell metabolism. In triple-negative breast cancer (TNBC) cells, we find that the expression of LIPG is associated with long non-coding RNA DANCR and positively correlates with gene signatures of mitochondrial metabolism-oxidative phosphorylation (OXPHOS). DANCR binds to LIPG, which enables tumor cells to maintain the expression. Importantly, LIPG knockdown inhibits OXPHOS and TNBC tumor formation. Finally, our study identifies a natural compound, the LIPG inhibitor cynaroside, which provides a new therapeutic strategy against TNBC. Abstract Triple-negative breast cancer (TNBC) cells reprogram their metabolism to provide metabolic flexibility for tumor cell growth and survival in the tumor microenvironment. While our previous findings indicated that endothelial lipase (EL/LIPG) is a hallmark of TNBC, the precise mechanism through which LIPG instigates TNBC metabolism remains undefined. Here, we report that the expression of LIPG is associated with long non-coding RNA DANCR and positively correlates with gene signatures of mitochondrial metabolism-oxidative phosphorylation (OXPHOS). DANCR binds to LIPG, enabling tumor cells to maintain LIPG protein stability and OXPHOS. As one mechanism of LIPG in the regulation of tumor cell oxidative metabolism, LIPG mediates histone deacetylase 6 (HDAC6) and histone acetylation, which contribute to changes in IL-6 and fatty acid synthesis gene expression. Finally, aided by a relaxed docking approach, we discovered a new LIPG inhibitor, cynaroside, that effectively suppressed the enzyme activity and DANCR in TNBC cells. Treatment with cynaroside inhibited the OXPHOS phenotype of TNBC cells, which severely impaired tumor formation. Taken together, our study provides mechanistic insights into the LIPG modulation of mitochondrial metabolism in TNBC and a proof-of-concept that targeting LIPG is a promising new therapeutic strategy for the treatment of TNBC.
Collapse
|
2
|
Lo PK, Yao Y, Zhou Q. Inhibition of LIPG phospholipase activity suppresses tumor formation of human basal-like triple-negative breast cancer. Sci Rep 2020; 10:8911. [PMID: 32488004 DOI: 10.1038/s41598-020-65400-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 05/04/2020] [Indexed: 01/10/2023] Open
Abstract
The endothelial lipase LIPG possesses serine phospholipase activity and is involved in lipoprotein metabolism. Our previous studies have revealed that LIPG overexpression is required for tumor formation and metastasis of human basal-like triple-negative breast cancer (TNBC). We also demonstrated that LIPG differentially regulates TNBC malignancy through its enzymatic and non-enzymatic functions. The present studies were aimed at determining how XEN445, a specific inhibitor targeting LIPG phospholipase activity, impacts on TNBC tumor formation and malignant features. We established a cell-based LIPG enzymatic assay system to measure the inhibitory effect of XEN445 on LIPG phospholipase activity and determine its IC50. We found that XEN445 preferentially inhibited the proliferation of LIPG-expressing TNBC cells but not LIPG-negative luminal breast cancer cells. XEN445 inhibited the self-renewal of cancer stem cells (CSCs) in vitro and TNBC tumor formation in vivo. However, XEN445 had no inhibitory effect on the invasiveness and CSC stemness of TNBC cells. Our studies suggest that targeting both LIPG enzymatic and non-enzymatic functions is an important strategy for the treatment of TNBC.
Collapse
|
3
|
Tora G, Kim SH, Pi Z, Johnson JA, Jiang J, Phillips M, Lloyd J, Abell LM, Lu H, Locke G, Adam LP, Taylor DS, Yin X, Behnia K, Zhao L, Yang R, Basso M, Caporuscio C, Chen AY, Liu E, Kirshgessner T, Onorato JM, Ryan C, Traeger SC, Gordon D, Wexler RR, Finlay HJ. Identification of Reversible Small Molecule Inhibitors of Endothelial Lipase (EL) That Demonstrate HDL-C Increase In Vivo. J Med Chem 2020; 63:1660-1670. [PMID: 31990537 DOI: 10.1021/acs.jmedchem.9b01831] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Endothelial lipase (EL) hydrolyzes phospholipids in high-density lipoprotein (HDL) resulting in reduction in plasma HDL levels. Studies with murine transgenic, KO, or loss-of-function variants strongly suggest that inhibition of EL will lead to sustained plasma high-density lipoprotein cholesterol (HDL-C) increase and, potentially, a reduced cardiovascular disease (CVD) risk. Herein, we describe the discovery of a series of oxadiazole ketones, which upon optimization, led to the identification of compound 12. Compound 12 was evaluated in a mouse pharmacodynamics (PD) model and demonstrated a 56% increase in plasma HDL-C. In a mouse reverse cholesterol transport study, compound 12 stimulated cholesterol efflux by 53% demonstrating HDL-C functionality.
Collapse
|
4
|
Meng W, Adam LP, Behnia K, Zhao L, Yang R, Kopcho LM, Locke GA, Taylor DS, Yin X, Wexler RR, Finlay H. Benzothiazole-based compounds as potent endothelial lipase inhibitors. Bioorg Med Chem Lett 2019; 29:126673. [DOI: 10.1016/j.bmcl.2019.126673] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2019] [Revised: 09/03/2019] [Accepted: 09/04/2019] [Indexed: 10/26/2022]
|
5
|
Kim SH, Johnson JA, Jiang J, Parkhurst B, Phillips M, Pi Z, Qiao JX, Tora G, Ye Chen A, Liu E, Yin X, Yang R, Zhao L, Taylor DS, Basso M, Behnia K, Onorato J, Chen XQ, Abell LM, Lu H, Locke G, Caporuscio C, Adam LP, Gordon D, Wexler RR, Finlay HJ. Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase. Bioorg Med Chem Lett 2019; 29:1918-1921. [PMID: 31176700 DOI: 10.1016/j.bmcl.2019.05.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Revised: 05/22/2019] [Accepted: 05/24/2019] [Indexed: 12/13/2022]
Abstract
A low level of high density lipoprotein (HDL) is an independent risk factor for cardiovascular disease. HDL reduces inflammation and plays a central role in reverse cholesterol transport, where cholesterol is removed from peripheral tissues and atherosclerotic plaque. One approach to increase plasma HDL is through inhibition of endothelial lipase (EL). EL hydrolyzes phospholipids in HDL resulting in reduction of plasma HDL. A series of benzothiazole sulfone amides was optimized for EL inhibition potency, lipase selectivity and improved pharmacokinetic profile leading to the identification of Compound 32. Compound 32 was evaluated in a mouse pharmacodynamic model and found to show no effect on HDL cholesterol level despite achieving targeted plasma exposure (Ctrough > 15 fold over mouse plasma EL IC50 over 4 days).
Collapse
Affiliation(s)
- Soong-Hoon Kim
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States.
| | - James A Johnson
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Ji Jiang
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Brandon Parkhurst
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Monique Phillips
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Zulan Pi
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Jennifer X Qiao
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - George Tora
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Alice Ye Chen
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Eddie Liu
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Xiaohong Yin
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Richard Yang
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Lei Zhao
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - David S Taylor
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Michael Basso
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Kamelia Behnia
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Joelle Onorato
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Xue-Qing Chen
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Lynn M Abell
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Hao Lu
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Gregory Locke
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Christian Caporuscio
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Leonard P Adam
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - David Gordon
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Ruth R Wexler
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| | - Heather J Finlay
- Research and Development, Bristol-Myers Squibb, Princeton, NJ 08543, United States
| |
Collapse
|
6
|
Johnson JA, Tora G, Pi Z, Phillips M, Yin X, Yang R, Zhao L, Chen AY, Taylor DS, Basso M, Rose A, Behnia K, Onorato J, Chen XQ, Abell LM, Lu H, Locke G, Caporuscio C, Galella M, Adam LP, Gordon D, Wexler RR, Finlay HJ. Sulfonylated Benzothiazoles as Inhibitors of Endothelial Lipase. ACS Med Chem Lett 2018; 9:1263-1268. [PMID: 30613337 DOI: 10.1021/acsmedchemlett.8b00424] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2018] [Accepted: 11/19/2018] [Indexed: 12/13/2022] Open
Abstract
Endothelial lipase (EL) selectively metabolizes high density lipoprotein (HDL) particles. Inhibition of EL has been shown to increase HDL concentration in preclinical animal models and was targeted as a potential treatment of atherosclerosis. We describe the introduction of an α-sulfone moiety to a benzothiazole series of EL inhibitors resulting in increased potency versus EL. Optimization for selectivity versus hepatic lipase and pharmacokinetic properties resulted in the discovery of 24, which showed good in vitro potency and bioavailability but, unexpectedly, did not increase HDL in the mouse pharmacodynamic model at the target plasma exposure.
Collapse
|
7
|
Hangeland JJ, Abell LM, Adam LP, Jiang J, Friends TJ, Haque LE, Neels J, Onorato JM, Chen AYA, Taylor DS, Yin X, Harrity TW, Basso MD, Yang R, Sleph PG, Gordon DA, Huang CS, Wexler RR, Finlay HJ, Lawrence RM. PK/PD Disconnect Observed with a Reversible Endothelial Lipase Inhibitor. ACS Med Chem Lett 2018; 9:673-678. [PMID: 30034599 DOI: 10.1021/acsmedchemlett.8b00138] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2018] [Accepted: 05/14/2018] [Indexed: 11/30/2022] Open
Abstract
Screening of a small set of nonselective lipase inhibitors against endothelial lipase (EL) identified a potent and reversible inhibitor, N-(3-(3,4-dichlorophenyl)propyl)-3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridine-4-carboxamide (5; EL IC50 = 61 nM, ELHDL IC50 = 454 nM). Deck mining identified a related hit, N-(3-(3,4-dichlorophenyl)propyl)-4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (6a; EL IC50 = 41 nM, ELHDL IC50 = 1760 nM). Both compounds were selective against lipoprotein lipase (LPL) but nonselective versus hepatic lipase (HL). Optimization of compound 6a for EL inhibition using HDL as substrate led to N-(4-(3,4-dichlorophenyl)butan-2-yl)-1-ethyl-4-hydroxy-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxamide (7c; EL IC50 = 148 nM, ELHDL IC50 = 218 nM) having improved PK over compound 6a, providing a tool molecule to test for the ability to increase HDL-cholesterol (HDL-C) levels in vivo using a reversible EL inhibitor. Compound 7c did not increase HDL-C in vivo despite achieving plasma exposures targeted on the basis of enzyme activity and protein binding demonstrating the need to develop more physiologically relevant in vitro assays to guide compound progression for in vivo evaluation.
Collapse
Affiliation(s)
- Jon J. Hangeland
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Lynn M. Abell
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Leonard P. Adam
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Ji Jiang
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Todd J. Friends
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Lauren E. Haque
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - James Neels
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Joelle M. Onorato
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Alice Ye A. Chen
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - David S. Taylor
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Xiaohong Yin
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Thomas W. Harrity
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Michael D. Basso
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Richard Yang
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Paul G. Sleph
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - David A. Gordon
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Christine S. Huang
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Ruth R. Wexler
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - Heather J. Finlay
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| | - R. Michael Lawrence
- Research and Development, Bristol-Myers Squibb, Princeton, New Jersey 08543, United States
| |
Collapse
|
8
|
Sun S, Dean R, Jia Q, Zenova A, Zhong J, Grayson C, Xie C, Lindgren A, Samra P, Sojo L, van Heek M, Lin L, Percival D, Fu JM, Winther MD, Zhang Z. Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice. Bioorg Med Chem 2013; 21:7724-34. [PMID: 24211162 DOI: 10.1016/j.bmc.2013.10.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2013] [Revised: 10/08/2013] [Accepted: 10/17/2013] [Indexed: 10/26/2022]
Abstract
Endothelial lipase (EL) activity has been implicated in HDL metabolism and in atherosclerotic plaque development; inhibitors are proposed to be efficacious in the treatment of dyslipidemia related cardiovascular disease. We describe here the discovery of a novel class of anthranilic acids EL inhibitors. XEN445 (compound 13) was identified as a potent and selective EL inhibitor, that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.
Collapse
Affiliation(s)
- Shaoyi Sun
- Xenon Pharmaceuticals Inc, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|